The Life Sciences Report

"DMPI's VAL-083 is a first-in-class small-molecule chemotherapeutic." (4/17/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Grant Zeng More >

"There is great potential for NEO to grow in the future." (4/17/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >

"SNGX has a very diversified pipeline under development; its Phase 2 trial for SGX924 is going very well." (4/17/14) Soligenix Inc. - The Life Sciences Report Interview with Grant Zeng More >

"RXII has some very important valuation-driving events in progress." (4/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More >

"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >